View in EDS

Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias.

Saved in:
Bibliographic Details
Title: Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias.
Authors: Zhang W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Li L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Muftuoglu M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Basyal M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Togashi N; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Iwanaga K; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Tanzawa F; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Numata M; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Bixby DL; Hematologic Oncology, University of Michigan Medical School, Ann Arbor, Michigan., Erba HP; Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina., Podoltsev N; Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut., Schiller GJ; Hematologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California., Kumar P; Daiichi Sankyo, Inc., Basking Ridge, New Jersey., Lesegretain A; Daiichi Sankyo, Inc., Basking Ridge, New Jersey., Isoyama T; Daiichi Sankyo Co., Ltd., Tokyo, Japan., Seki T; Daiichi Sankyo, Inc., Basking Ridge, New Jersey., Daver N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas., Andreeff M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Jul 15; Vol. 31 (14), pp. 3033-3047.
Publication Type: Journal Article; Clinical Trial, Phase I
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40327322
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Zhang+W%22">Zhang W</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Li+L%22">Li L</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Muftuoglu+M%22">Muftuoglu M</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Basyal+M%22">Basyal M</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Togashi+N%22">Togashi N</searchLink>; Daiichi Sankyo Co., Ltd., Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Iwanaga+K%22">Iwanaga K</searchLink>; Daiichi Sankyo Co., Ltd., Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Tanzawa+F%22">Tanzawa F</searchLink>; Daiichi Sankyo Co., Ltd., Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Numata+M%22">Numata M</searchLink>; Daiichi Sankyo Co., Ltd., Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Bixby+DL%22">Bixby DL</searchLink>; Hematologic Oncology, University of Michigan Medical School, Ann Arbor, Michigan.<br /><searchLink fieldCode="AU" term="%22Erba+HP%22">Erba HP</searchLink>; Hematologic Malignancies and Cellular Therapy, Duke University, Durham, North Carolina.<br /><searchLink fieldCode="AU" term="%22Podoltsev+N%22">Podoltsev N</searchLink>; Hematology Section, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.<br /><searchLink fieldCode="AU" term="%22Schiller+GJ%22">Schiller GJ</searchLink>; Hematologic Oncology, David Geffen School of Medicine at UCLA, Los Angeles, California.<br /><searchLink fieldCode="AU" term="%22Kumar+P%22">Kumar P</searchLink>; Daiichi Sankyo, Inc., Basking Ridge, New Jersey.<br /><searchLink fieldCode="AU" term="%22Lesegretain+A%22">Lesegretain A</searchLink>; Daiichi Sankyo, Inc., Basking Ridge, New Jersey.<br /><searchLink fieldCode="AU" term="%22Isoyama+T%22">Isoyama T</searchLink>; Daiichi Sankyo Co., Ltd., Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Seki+T%22">Seki T</searchLink>; Daiichi Sankyo, Inc., Basking Ridge, New Jersey.<br /><searchLink fieldCode="AU" term="%22Daver+N%22">Daver N</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.<br /><searchLink fieldCode="AU" term="%22Andreeff+M%22">Andreeff M</searchLink>; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2025 Jul 15; Vol. 31 (14), pp. 3033-3047.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40327322
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-24-2764
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 3033
    Titles:
      – TitleFull: Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition with Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild-type Acute Myeloid Leukemias.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Zhang W
      – PersonEntity:
          Name:
            NameFull: Li L
      – PersonEntity:
          Name:
            NameFull: Muftuoglu M
      – PersonEntity:
          Name:
            NameFull: Basyal M
      – PersonEntity:
          Name:
            NameFull: Togashi N
      – PersonEntity:
          Name:
            NameFull: Iwanaga K
      – PersonEntity:
          Name:
            NameFull: Tanzawa F
      – PersonEntity:
          Name:
            NameFull: Numata M
      – PersonEntity:
          Name:
            NameFull: Bixby DL
      – PersonEntity:
          Name:
            NameFull: Erba HP
      – PersonEntity:
          Name:
            NameFull: Podoltsev N
      – PersonEntity:
          Name:
            NameFull: Schiller GJ
      – PersonEntity:
          Name:
            NameFull: Kumar P
      – PersonEntity:
          Name:
            NameFull: Lesegretain A
      – PersonEntity:
          Name:
            NameFull: Isoyama T
      – PersonEntity:
          Name:
            NameFull: Seki T
      – PersonEntity:
          Name:
            NameFull: Daver N
      – PersonEntity:
          Name:
            NameFull: Andreeff M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 15
              M: 07
              Text: 2025 Jul 15
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 31
            – Type: issue
              Value: 14
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1